The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Open accessAbstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers. Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“analyses of samples derived from patients with melanoma who received neoadjuvant ICIs112,113 have revealed the presence of the three primary patterns of T cell infiltration identified in solid tumours.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [113]
Experimental — accuracy not yet measuredIn the citing paper
“Studies in melanoma using higher dosages of ipilimumab reported enhanced immune infiltration in responding tumors17.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Amaria and colleagues17 demonstrated that a more clonal T-cell repertoire at baseline correlated with response to neoadjuvant ICI therapy in patients with melanoma, with further expansion of the pre-existing high-frequency clones with treatment.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Key roles of TGF-β1 in suppressing the adaptive immune system are apparent from the lymphoproliferative autoimmune phenotype of Tgfb1−/− mice197–199, and similar phenotypes following selective ablation of TGF-β signaling components within CD4+ and CD8+ T cells200.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [198]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,508
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,055
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Research works printed but not linked: 1
- Edge, S. B. AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
Cited by
Sorted by citations
Items 401–500 of 838
van Akkooi, A. C. J., Mandalà, M., Nathan, P., Haydon, A. M., Postow, M. A., & Rutkowski, P. L. (2024) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2024.100021 · Cited by 17
Review of recent advances in managing periocular skin malignancies
Trotier, D., Huang, L., van Landingham, S. W., Burr, A. R., & Ma, V. T.-L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1275930 · Cited by 18
Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla, N., Ghandour, R. A., & Margulis, V. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000659 · Cited by 16
The Emergence of Neoadjuvant Therapy in Advanced Melanoma
Sun, J. X., Kirichenko, D. A., Zager, J. S., & Eroglu, Z. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0007 · Cited by 16
Abdelhafeez, A. A. M., Shohdy, K. S., & Ibrahim, W. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1714053 · Cited by 16
Neoadjuvant BRAF‐targeted therapy in regionally advanced and oligometastatic melanoma
Eroglu, Z., Eatrides, J. M., Naqvi, S. M. H., Kim, Y., Rich, J., Babacan, N. A., Brohl, A. S., Markowitz, J., Sarnaik, A. A., Zager, J. S., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12813 · Cited by 16
Targeting novel inhibitory receptors in cancer immunotherapy
Ding, Q., Chauvin, J.-M., & Zarour, H. M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101436 · Cited by 16
Guo, R., Peng, J.-Z., Li, Y., & Li, X. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2112007 · Cited by 15
The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma
Bushara, O., Tidwell, J. C., Wester, J. R., & Miura, J. T. (2023) · Cancers · doi:10.3390/cancers15133344 · Cited by 15
Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?
Berghoff, A. S., & Preusser, M. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0178-0 · Cited by 15
Ascierto, P. A., Agarwala, S. S., Botti, G., Budillon, A., Davies, M. A., Dummer, R., Ernstoff, M. S., Ferrone, S., Formenti, S. C., Gajewski, T. F., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1979-z · Cited by 15
Self-citationSun, J. X., Kirichenko, D. A., Chung, J. L., Carr, M. J., Eroglu, Z., Khushalani, N. I., Markowitz, J., Messina, J. L., Sondak, V. K., Zager, J. S., et al. (2019) · World Journal of Surgery · doi:10.1007/s00268-019-05314-2 · Cited by 16
Self-citationCan patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?
Arrieta, V. A., IWAMOTO, F. M., Lukas, R. V., Sachdev, S., Rabadán, R., & Sonabend, A. M. (2019) · Journal of neurosurgery · doi:10.3171/2019.9.jns192523 · Cited by 15
Song, Y., Straker, R. J., Xu, X., Elder, D. E., Gimotty, P. A., Huang, A. C. C., Mitchell, T. C., Amaravadi, R. K., Schuchter, L. M., & Karakousis, G. C. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08174-1 · Cited by 16
Khunger, A., Sarikonda, G., Tsau, J., Pahuja, A., Alfonso, Z., Gao, J., Laing, C., Vaupel, C., Dakappagari, N. K., & Tarhini, A. A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101014 · Cited by 15
High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
Quek, C. Y. J., Bai, X., Long, G. V., Scolyer, R. A., & Wilmott, J. S. (2021) · Genes · doi:10.3390/genes12101629 · Cited by 16
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 16
Chen, Z., John, J., & Wang, J. H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.995434 · Cited by 19
Nabbi, A., Danesh, A., Espin‐Garcia, O., Pedersen, S., Wellum, J., Fu, L. H., Paulson, J. N., Geoerger, B., Marshall, L. V., Trippett, T. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00534-x · Cited by 17
Tertiary lymphoid structures: exploring opportunities to improve immunotherapy in ovarian cancer
Varghese, A., Hess, S. M., Chilakapati, S. R., Conejo-Garcia, J. R., McGray, A. R., & Zsíros, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1473969 · Cited by 14
Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy
Chiffelle, J., Genolet, R., Michielin, O. A., & Harari, A. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101076 · Cited by 14
Chakrabarti, S., Grewal, U. S., Vora, K. B., Parikh, A. R., Almader‐Douglas, D., Mahipal, A., & Sonbol, M. B. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00182 · Cited by 15
Țăpoi, D. A., Derewicz, D., Gheorghișan-Gălățeanu, A.-A., Dumitru, A. V., Ciongariu, A. M., & Costache, M. (2023) · Biomedicines · doi:10.3390/biomedicines11102616 · Cited by 14
Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence
Vaidya, P., & Cohen, E. E. W. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0583 · Cited by 15
Advances in tissue-based imaging: impact on oncology research and clinical practice
Rahman, A., Jahangir, C. A., Lynch, S. M., Al-Attar, N., Aura, C. M., Russell, N. M., Lanigan, F. T., & Gallagher, W. M. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1770599 · Cited by 15
Shao, L., & Lou, G. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1192 · Cited by 13
Zhang, P., Xiong, X., Rolfo, C. D., Du, X., Zhang, Y., Yang, H., Russo, A., Devenport, M., Zhou, P., Liu, Y., et al. (2020) · Cancers · doi:10.3390/cancers12020284 · Cited by 14
Chen, Q., Yin, H., Pu, N., Zhang, J., Zhao, G., Lou, W., & Wu, W. (2021) · Cancer Science · doi:10.1111/cas.15110 · Cited by 16
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C. M., Hwu, W., Hanna, E. Y., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0251-z · Cited by 14
Self-citationCheng, T., Wu, Y., & Wu, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616872 · Cited by 13
Burns, T. F., Ammakkanavar, N. R., Hollebecque, A., Lee, D. H., Koyama, T., Cassier, P. A., Italiano, A., Han, J., Singhal, N., Takeuchi, S., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.11.018 · Cited by 14
Guo, J., Hsu, C., Huang, Y., Lin, C., Huang, T., Wu, I., Lin, C., Lien, M., Kuo, H., Cheng, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879398 · Cited by 13
Chen, J., Deng, H., He, J., Wang, Z., & Li, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909726 · Cited by 13
Zijlker, L. P., van der Burg, S. J. C., Blank, C. U., Zuur, C. L., Klop, W. M. C., Wouters, M. W. J. M., van Houdt, W. J., & van Akkooi, A. C. J. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.003 · Cited by 14
Immunotherapy for Neuro-Oncology
Majd, N., Dasgupta, P., & de Groot, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_8 · Cited by 13
Wang, N., Wang, R., Zhang, X., Li, X., Liang, Y., & Ding, Z. (2021) · Visualized Cancer Medicine · doi:10.1051/vcm/2020002 · Cited by 13
Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review
Boulva, K., Apte, S. S., Yu, A. M., Tran, A., Shorr, R., Song, X., Ong, M., & Nessim, C. (2021) · Cancers · doi:10.3390/cancers13081905 · Cited by 13
Indini, A., Roila, F., Grossi, F., Massi, D., & Mandalà, M. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00608-5 · Cited by 12
Sun, Y., Jiang, L., Wen, T., Guo, X., Shao, X., Qu, H., Chen, X., Song, Y., Wang, F., Qu, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670900 · Cited by 13
Zhang, S., Chen, S., Wang, Y., Zhan, Y., Li, J., Nong, X., & Gao, B. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.744304 · Cited by 13
Self-citationPreoperative therapy in melanoma: Evolving perspectives in clinical trials
Kakish, H. H., Xu, K. Y., Ahmed, F. A., Loftus, A. W., Elshami, M., Hoehn, R. S., Ammori, J. B., Mangla, A., & Rothermel, L. D. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104193 · Cited by 13
Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon
Helmink, B. A., Roland, C. L., Kiernan, C. M., & Wargo, J. A. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08183-0 · Cited by 13
Self-citationKoldej, R. M., & Ritchie, D. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.02.001 · Cited by 13
Bai, X. L., Kim, M. H., Kasumova, G. G., Si, L., Tang, B., Cui, C., Yang, X., Wei, X., Cohen, J. V., Lawrence, D. P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002092 · Cited by 13
Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma
Bruce, W. J., Koljonen, J. L., Romanelli, M. R., Khan, A. U., & Neumeister, M. W. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.06.001 · Cited by 14
Biomarkers and immunotherapy: where are we?
Fontsa, M. L., Padonou, F., & Willard-Gallo, K. E. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000891 · Cited by 13
Delpeuch, F., Joseph, A., & Cavelier, C. (1975) · PubMed · Cited by 13
Cao, W., Hu, H., Li, J., Wu, Q., Shi, L., Li, B., Zhou, J., Wang, X., Chen, J., Wang, C., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34647 · Cited by 13
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity
Lucas, M. W., Burton, E. M., Dimitriadis, P., Huang, A. C. C., Long, G. V., Mitchell, T. C., Amaria, R. N., & Blank, C. U. (2025) · Immunity · doi:10.1016/j.immuni.2025.11.021 · Cited by 15
Self-citationHoeijmakers, L. L., Dimitriadis, P., Wijnen, S. C. M. A., Reijers, I. L. M., López‐Yurda, M., Menzies, A. M., Broeks, A., Cornelissen, S., Acosta, A. T., van der Wal, A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04158-9 · Cited by 13
Salem, A. F., Chen, M., Williams, M. D., Swanson, D. M., McQuade, J. L., Amaria, R. N., Hanna, E. Y., Bishop, A. J., Farooqi, A. S., Guadagnolo, B. A., et al. (2025) · Head & Neck · doi:10.1002/hed.28098 · Cited by 14
Self-citationBolzacchini, E., Libera, L., Church, S., Sahnane, N., Bombelli, R., Digiacomo, N., Giordano, M., Petracco, G., Sessa, F., Capella, C., et al. (2022) · Cancers · doi:10.3390/cancers14163951 · Cited by 12
Prognostic factors for pulmonary metastasectomy in malignant melanoma: size matters
Viehof, J., Livingstone, E., Loscha, E., Stockhammer, P., Bánkfalvi, Á., Plönes, T., Mardanzai, K., Zimmer, L., Sucker, A., Schadendorf, D., et al. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz211 · Cited by 12
Tapia, C., Aung, P. P., Roy‐Chowdhuri, S., Xu, M., Ouyang, F., Alshawa, A., Hajjar, J., Singh, G., Yang, V. W., Castillo, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000665 · Cited by 12
The Role of Neoadjuvant Therapy in Melanoma
Kelly, Z. R., Gorantla, V. C., & Davar, D. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00944-5 · Cited by 12
Mano, R., Düzgöl, C., Ganat, M., Goldman, D. A., Blum, K. A., Silagy, A. W., Walasek, A., Sánchez, A., DiNatale, R. G., Marcon, J., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.07.019 · Cited by 12
Mueller, K. L., Theoret, M. R., Lemery, S. J., Amiri‐Kordestani, L., Ariyan, C. E., Atkins, M. B., Berry, D. A., Blank, C. U., DeMichele, A. M., Forde, P. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3285 · Cited by 12
Self-citationAdjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era
Straker, R. J., Song, Y., Sun, J. X., Shannon, A. B., Cohen, L. S., Muradova, E., Daou, H., Krause, K., Li, S., Frederick, D. T., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09384-8 · Cited by 13
Current management of melanoma patients with nodal metastases
Han, D., van Akkooi, A. C. J., Straker, R. J., Shannon, A. B., Karakousis, G. C., Wang, L., Kim, K. B., & Reintgen, D. S. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10099-7 · Cited by 13
Self-citationHuang, S., Zheng, G., & Yang, K. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03212-5 · Cited by 12
Tertiary Lymphoid Structure in Tumor Microenvironment and Immunotherapy of Lung Cancer
Xie, M., Lin, X., Bao, X., Liang, Y., Deng, H., Song, J., Ma, X., Zhang, X., Yao, J., Pan, L., et al. (2024) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2024.07.020 · Cited by 11
Liu, C., Li, M., Liu, X., Shi, T., Wang, Y., Sui, C.-Y., Zhang, W.-A., & Wang, B.-W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1467306 · Cited by 13
Human TCR repertoire in cancer
Chen, L., Hu, Y., Zheng, B., Luo, L., & Su, Z. (2024) · Cancer Medicine · doi:10.1002/cam4.70164 · Cited by 11
CD4 + FOXP3Exon2 + regulatory T cell frequency predicts breast cancer prognosis and survival
Fusco, C., Rella, F. D., Liotti, A., Colamatteo, A., Ferrara, A. L., Gigantino, V., Collina, F., Esposito, E., Donzelli, I., Porcellini, A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr7934 · Cited by 13
Wang, V. E., Blaser, B. W., Patel, R. K., Behbehani, G. K., Rao, A. A., Durbin-Johnson, B., Jiang, T., Logan, A. C., Settles, M., Mannis, G. N., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0055 · Cited by 11
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients
Marx, S., Wilken, F., Miebach, L., Ispirjan, M., Kinnen, F., Paúl, S., Bien-Möller, S., Freund, E., Baldauf, J., Fleck, S. K., et al. (2022) · Cancers · doi:10.3390/cancers14235751 · Cited by 11
Update on tumor metabolism and patterns of response to immunotherapy
Castello, A., & Lopci, E. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03251-3 · Cited by 11
Cross‐talk between tumors at anatomically distinct sites
Oliver, A. J., Darcy, P. K., Trapani, J. A., Kershaw, M. H., & Slaney, C. Y. (2020) · FEBS Journal · doi:10.1111/febs.15316 · Cited by 11
Khunger, A., Piazza, E., Warren, S. E., Smith, T. H., Ren, X., White, A. M., Elliott, N., Cesano, A., Beechem, J., Kirkwood, J. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245287 · Cited by 11
Sweeney, K. J., Tetzlaff, M. T., Vega, F., Gillenwater, A. M., Zuo, Z., Gross, N. D., Nagarajan, P., Wargo, J. A., Nelson, K. C., Prieto, V. G., et al. (2021) · Journal of Cutaneous Pathology · doi:10.1111/cup.13953 · Cited by 11
Self-citationIdentification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy
Zheng, X., Gao, Y., Yu, C., Fan, G., Li, P., Zhang, M., Yu, J., & Xu, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-98966-x · Cited by 11
Moyers, J. T., & Oliva, I. C. G. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_3 · Cited by 11
Omotesho, Q. A., Escamilla, A., Pérez-Ruiz, E., Frecha, C. A., Rueda‐Domínguez, A., & Barragán, I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348156 · Cited by 10
Campbell, M. J., Wolf, D. M., Yau, C. S. F., Swigart, L. B., Wulfkuhle, J., Gallagher, R. I., Zhu, Z., Bolen, J., VandenBerg, S. R., Hoyt, C. C., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101799 · Cited by 10
Bai, J., Wan, Z., Zhou, W., Wang, L., Lou, W., Zhang, Y., & Jin, H. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1538743 · Cited by 10
Self-citationMelanoma neoadjuvant treatment: review and update of recent trials
Ferrari, M., Facchini, B. A., Ascierto, P. A., & Sparano, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2474182 · Cited by 11
Ma, L., Luan, Y., & Lü, L. (2025) · Cancer Medicine · doi:10.1002/cam4.70622 · Cited by 11
Review: radiotherapy-mediated B cells within the TLS influence the tumor microenvironment
Yang, H., Chen, K., Meng, Y., Chen, Z., Xu, Y., Zhou, D., Zhou, S., & Zhang, X. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011617 · Cited by 11
Kamatani, T., Umeda, K., Iwasawa, T., Miya, F., Matsumoto, K., Mikami, S., Hara, K., Shimoda, M., Suzuki, Y., Nishino, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63309-1 · Cited by 10
Primary and metastatic breast tumors cross-talk to influence immunotherapy responses
Oliver, A. J., Keam, S. P., von Scheidt, B., Zanker, D. J., Harrison, A. J., Tantalo, D. G. M., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1802979 · Cited by 10
Kamat, S., Patel, J., Brown, B. R., & Vyas, A. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2108827 · Cited by 12
Venzel, R., Campos, M. C. P., de Oliveira, L. P., Lins, R. V. D., Siena, Á. D. D., Mesquita, K. T., dos Santos, T. P. M., Nohata, N., Arruda, L. C. M., Sales‐Campos, H., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103988 · Cited by 10
Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma
Su, D. G., Kluger, H. M., & Olino, K. L. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14587-w · Cited by 10
Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer
Gherman, A., Bolunduț, D., Ecea, R., Bălăcescu, L., Curcean, S., Dina, C., Bălăcescu, O., & Cainap, C. I. (2024) · Medicina · doi:10.3390/medicina60030397 · Cited by 10
From foes to friends: rethinking the role of lymph nodes in prostate cancer
Gupta, R., Das, C. K., Nair, S. S., Pedraza, A. M., Zahalka, A. H., Kyprianou, N., Bhardwaj, N., & Tewari, A. K. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00912-9 · Cited by 11
Beasley, G. M., Therien, A. D., Holl, E. K., Al-Rohil, R. N., Selim, M. A., Farrow, N. E., Pan, L., Haynes, P., Liang, Y., Tyler, D. S., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02698-2 · Cited by 11
Lim, A. M. L., Cavanagh, K., Hicks, R. J., McLean, L. S., Goh, M., Webb, A., & Rischin, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656611 · Cited by 10
Willis, J. E., Eyerer, F., Walk, E. E., Vasalos, P., Bradshaw, G., Yohe, S. L., & Laser, J. S. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0151-cp · Cited by 10
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma
Levine, L. S., Mahuron, K. M., Tsai, K. K., Wu, C., Mattis, D. M., Pauli, M. L., Oglesby, A., Lee, J., Spitzer, M. H., Krummel, M. F., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08648-7 · Cited by 10
Self-citationNeoadjuvant immune checkpoint inhibitors in cancer, current state of the art
Saux, O. L., Lounici, Y., Wajda, P., Ghamry-Barrin, S., Caux, C., Dubois, B., & Ray-Coquard, I. L. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103172 · Cited by 10
The Biology of Immune-Active Cancers and Their Regulatory Mechanisms
Bedognetti, D., Cesano, A., Marincola, F. M., & Wang, E. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_5 · Cited by 9
Alvarez, J., & Smith, J. (2023) · Seminars in Colon and Rectal Surgery · doi:10.1016/j.scrs.2023.100990 · Cited by 8
Therapeutic Treatment Options for In-Transit Metastases from Melanoma
Russano, F., Rastrelli, M., Dall’Olmo, L., Fiore, P. D., Gianesini, C. M., Vecchiato, A., Mazza, M., Tropea, S., & D, S. M. M. (2024) · Cancers · doi:10.3390/cancers16173065 · Cited by 11
Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers
Ellebæk, E., Donia, M., & Svane, I. M. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115257 · Cited by 9
The “double-edged sword” effect of cytokines in cancer: coexisting opportunities and challenges
Yin, X., Zhang, W., Wang, G., Liu, Y., Dai, B., & Yue, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1701405 · Cited by 10
TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how
Nose, Y., Figueiredo, I., Tuballes, K., Valle, D. M. D., Gonsalves, T. R., Guo, R., Ioannou, G., Cabal, R., Gonzalez‐Kozlova, E., & Gnjatic, S. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013499 · Cited by 9
Okuyama, K., Naruse, T., Matsushita, Y., Fujimoto, J., Yanamoto, S., Lei, Y. L., & Hu, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02609-6 · Cited by 9
Burton, E. M., Amaria, R. N., Cascone, T., Chalabi, M., Gross, N. D., Mittendorf, E. A., Scolyer, R. A., Sharma, P., & Ascierto, P. A. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03472-x · Cited by 9
Self-citationRole of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation
Ouranos, K., Chatziioannou, A., Goulis, I., & Sinakos, E. (2022) · World Journal of Transplantation · doi:10.5500/wjt.v12.i11.331 · Cited by 9
Thai, A. A., Young, R. J., Bressel, M., Angel, C. M., McDowell, L. J., Tiong, A., Bucknell, N. W., FELLOWES, A. P., Xu, H., Trigos, A., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad250 · Cited by 10
Metadata
- Authors
- Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S., Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Wargo, Jennifer A.
- ORCID
- Amaria, Rodabe N.
- Reddy, Sangeetha M.
- Tawbi, Hussein A.
- Davies, Michael A.
- Ross, Merrick I.
- Cormier, Janice N.
- Lewis, Carol
- Hwu, Wen-Jen
- Hanna, Ehab
- Diab, Adi
- Wong, Michael K.
- Gross, Neil
- Weber, Randal
- Lai, Stephen Y.
- Blando, Jorge
- Woodman, Scott
- Kageyama, Robin
- Wells, Daniel K.
- Hwu, Patrick
- Patel, Sapna P.
- Lucci, Anthony
- Lee, Jeffrey E.
- Gershenwald, Jeffrey
- Burton, Elizabeth M.
- Haydu, Lauren
- Wang, Linghua
- Zhang, Shaojun
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Gopalakrishnan, Vancheswaran
- Reuben, Alexandre
- Andrews, Miles C.
- Spencer, Christine N.
- Prieto, Victor
- Sharma, Padmanee
- Allison, James
- Tetzlaff, Michael T.
- Wargo, Jennifer A.
- Venue
- Nature Medicine
- Published
- 2018-10-08
- Volume
- 24
- Issue
- 11
- Pages
- 1649-1654
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6481682
- OpenAlex
- W2894584497
- Semantic Scholar
- 251ac2984307dc31d5a4596caa7a07c90195b1e8
- Cited by
- 835
- References
- 31
- Citations by year
- 2026: 49 · 2025: 80 · 2024: 102 · 2023: 116 · 2022: 119 · 2021: 130 · 2020: 142 · 2019: 79 · 2018: 12
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Nature
- National Institutes of Health (UL1TR000371)
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (T32CA009666, K08CA160692)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, nivolumab, ipilimumab, combination immunotherapy, pathological complete response, T cell infiltration, lymphocyte infiltration, treatment-related adverse events, biomarkers
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Risk Factors, Disease-Free Survival, Neoadjuvant Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
